Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated the long-term cost-effectiveness of atorvastatin 20 mg, rosuvastatin 10 mg and simvastatin 40 mg in primary and secondary prevention of CHD in Finland. RESEARCH DESIGN AND METHODS: The effect of statin therapy on the incidence of CHD and the expected total costs of the disease were described using a Markov state transition model. Due to the limited amount of evidence concerning mortality and morbidity for rosuvastatin, the model was used to transmute the efficiency data of all statins (decrease in total cholesterol) into long-term endpoints (myocardial infarction, death) using risk functions of the FINRISK and 4S studies. The study followed a characterized cohort of 55-year-old Finnish men with an average 3.3-6.6% baseline risk of dying from cardiovascular disease within a 10-year period. MAIN OUTCOME MEASURES: Incremental cost-effectiveness ratios (ICERs) for atorvastatin and rosuvastatin, compared with simvastatin, measured as cost of life years gained (euro/LYG) and cost of quality adjusted life years gained (euro/QALY). RESULTS: The use of rosuvastatin increased the life expectancy by 0.27 years on average (LYG) compared with simvastatin, producing additional 0.08 quality-adjusted life-years (QALYs). Compared with simvastatin, the cost of one LYG with rosuvastatin was euro10 834 and the cost of one QALY gained was euro36 548 (discount rate 5% per annum). Corresponding figures for atorvastatin were euro31 286/LYG and euro105 599/QALY. CONCLUSIONS: If the decision makers' willingness to pay for a QALY gained is around euro40 000 there is a high probability (>50%) that rosuvastatin represents a cost-effective form of therapy in the prevention of CHD in middle-aged men with an average 3.3-6.6% risk of dying within 10 years from cardiovascular disease. However, the true clinical impact of these results needs confirmation from on-going clinical trials, as the role of rosuvastatin in reducing clinical events is pending, but for simvastatin and atorvastatin established.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [24]
Citations
Cites
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
The 15D instrument of health-related quality of life: properties and applications
Sintonen, H. (2001) · Annals of Medicine · doi:10.3109/07853890109002086 · Cited by 1,217
Devlin, N., & Parkin, D. (2004) · Health Economics · doi:10.1002/hec.864 · Cited by 709
Economic burden of cardiovascular diseases in the enlarged European Union
Leal, J., Luengo-Fernández, R., Gray, A., Petersen, S., & Rayner, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi733 · Cited by 698
Research works printed but not linked: 6
- National Agency for Medicines and Social Insurance Institution, 2007, Finnish statistics on medicines 2006
- Davies A, 2006, Br J Cardiol, 13, 196
- Statistic Finland, 2002, Causes of death 2001
- Finnish National Public Health Institute, National cardiovascular disease register
- Hujanen T, 2003, Terveydenhuollon Yksikkökustannukset Suomessa Vuonna 2001. Aiheita 1/2003
- Väistö T, 2005, Finnish Med J, 60, 389
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Metadata
- Authors
- Peura, P., Martikainen, J., Soini, E., Hallinen, T., & Niskanen, L.
- Affiliations
- University of Eastern Finland (FI)
- ESiOR Oy (Finland) (FI)
- Kuopio University Hospital (FI)
- Corresponding author
- Peura, Piia
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2008-05-14
- Volume
- 24
- Issue
- 6
- Pages
- 1823-1832
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2142140912
- Cited by
- 29
- References
- 25
- Citations by year
- 2026: 1 · 2025: 1 · 2020: 1 · 2019: 4 · 2017: 6 · 2016: 4 · 2015: 1 · 2014: 1
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- statins, cost-effectiveness, coronary heart disease prevention, rosuvastatin, atorvastatin, simvastatin, middle-aged men, cardiovascular risk, quality-adjusted life years, life-years gained, cardiovascular mortality, myocardial infarction, Finnish men
- MeSH terms
- Rosuvastatin Calcium, Atorvastatin, Coronary Disease, Cost-Benefit Analysis, Finland, Fluorobenzenes, Heptanoic Acids, Humans, Life Expectancy, Male, Markov Chains, Middle Aged, Pyrimidines, Pyrroles, Sulfonamides, Cohort Studies, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. https://app.cochat.ai/papers/10.1185/03007990802144705
- The paper
- Peura, P., Martikainen, J., Soini, E., Hallinen, T., & Niskanen, L. (2008). Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Current Medical Research and Opinion. https://doi.org/10.1185/03007990802144705
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.